Researchers design contact lens to administer glaucoma drug

Article

Researchers at the University of California, Los Angeles, have designed a contact lens that can release controlled amounts of a glaucoma drug, delivering more consistent dosages of the drug than eye drops.

Los Angeles-Researchers at the University of California, Los Angeles, have designed a contact lens that can release controlled amounts of a glaucoma drug, delivering more consistent dosages of the drug than eye drops. 

Bioengineer Dean Ho, PhD, says eye drops often leak out of the eye and arrive in one high-concentrated burst that quickly tapers off, making dosages inconsistent. Ho aimed to make a daily-wear hydrogel contact lens that could release a drug throughout the day to provide a simple solution for glaucoma patients to get the necessary drugs. The lens uses nanodimaonds, faceted carbon particles about 5 nm in diameter, some of which are positively charges, while others are negatively charged. The nanoparticles attract water and can bind and release a variety of molecules.

Ho and the team of researchers at UCLA created a nanodiamond gel. When the gel comes in contact with lysozyme, an enzyme in tears, it breaks down and the drug is released. The gel was used to create a hydrogel lens, and, after some testing, the lens was able to steadily release timolol for 24 hours. After 48 hours, the drug release became less consistent, but researchers say that was not a concern because patients would likely replace the lenses daily.

“While drug-eluting contact lenses are nothing new, the lysozymal process in the gel of the lens is innovative and worth noting. Many of the problems other drug-eluting contact lenses have encountered in the allergy space will be issues with a glaucoma lens as well,” says Ben Gaddie, OD, in Louisville, KY. “Drug-eluting lenses can result in corneal toxicity from the drug or its preservatives, and contact lens-related dry eye and handling problems must be overcome in order for this to be a viable option. Consider having an 85-year-old patient handle a contact lens on a twice daily basis-this technology will have a steep hill to climb.”

Ho plans to test drug-releasing contact lenses in animals and will experiment with adjusting the timing of the drug release to test whether it will have any clinical benefit. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
© 2025 MJH Life Sciences

All rights reserved.